前列腺导管内癌对高危前列腺癌新辅助治疗效果的影响

Effect of presence of intraductal carcinoma of prostate in men with high-risk prostate cancer receiving neoadjuvant therapy

目的探究在局部高危前列腺癌患者中存在前列腺导管内癌(IDC-P)成分的患者对于新辅助治疗的反应情况。方法对南京大学医学院附属鼓楼医院的确诊为前列腺癌的80例患者进行回顾性研究分析,通过穿刺中是否存在IDC-P成分以及患者接受6个月新辅助治疗后大病理中客观缓解情况,以评估IDC-P患者接受新辅助治疗的疗效。结果高国际泌尿病理协会分级ISUP(P=0.037)、临床T分期(P=0.036)、神经侵犯有关(P=0.041)与IDC-P有关。单因素分析显示存在IDC-P是病理客观缓解(OR=8.022,95%CI:1.550~41.515,P=0.013)的影响因素。结论局部高危前列腺癌患者中含IDC-P成分对新辅助治疗效果更差。

Objective To study the effect of presence of intraductal prostate cancer(IDC-P)to locally high-risk prostate cancer patients receiving neoadjuvant therapy.Methods A retrospective study of 80 patients diagnosed as prostate cancer from Nanjing Drum Tower Hospital was conducted to evaluate the association of the presence of IDC-P on biopsy pathology with favorable pathologic objective response after receiving six-month neoadjuvant therapy.Results Patients with IDC-P were associated with higher ISUP(P=0.037),clinical T stage(P=0.036),and nerve invasion(P=0.041).Univariate analysis showed that patients with IDC-P were less likely to appear favorable pathologic response(OR=8.022,95%CI:1.550-41.515,P=0.013).Conclusions Patients with IDC-P were less sensitive to neoadjuvant therapy.